Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
19
CLPT Quote, Financials, Valuation and Earnings
Last price:
$11.38
Seasonality move
:
-0.11%
Day range:
$10.81 - $11.40
52-week range:
$6.25 - $19.22
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.69x
P/B ratio:
16.01x
Volume:
564.7K
Avg. volume:
496.2K
1-year change:
49.28%
Market cap:
$320.2M
Revenue:
$31.4M
EPS (TTM):
-$0.76
Analysts' Opinion
-
Consensus RatingClearPoint Neuro has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $29.00, ClearPoint Neuro has an estimated upside of 155.96% from its current price of $11.33.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $28.00 representing 100% downside risk from its current price of $11.33.
Fair Value
-
According to the consensus of 2 analysts, ClearPoint Neuro has 155.96% upside to fair value with a price target of $29.00 per share.
CLPT vs. S&P 500
-
Over the past 5 trading days, ClearPoint Neuro has underperformed the S&P 500 by -7.53% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
ClearPoint Neuro does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ClearPoint Neuro has grown year-over-year revenues for 19 quarters straight. In the most recent quarter ClearPoint Neuro reported revenues of $8.5M.
Earnings Growth
-
ClearPoint Neuro has grown year-over-year earnings for 0 quarters straight. In the most recent quarter ClearPoint Neuro reported earnings per share of -$0.22.
Enterprise value:
302.8M
EV / Invested capital:
--
Price / LTM sales:
9.69x
EV / EBIT:
--
EV / Revenue:
9.39x
PEG ratio (5yr expected):
-0.48x
EV / Free cash flow:
-25.79x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$19.7M
Return On Assets:
-48.21%
Net Income Margin (TTM):
-64.51%
Return On Equity:
-73.69%
Return On Invested Capital:
-64.56%
Operating Margin:
-72.63%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $21M | $26.2M | $32.2M | $7.6M | $8.5M | |
| Gross Profit | $13.5M | $14.9M | $19.7M | $4.5M | $5.1M | |
| Operating Income | -$18.2M | -$21M | -$21.7M | -$4.2M | -$6.2M | |
| EBITDA | -$17.4M | -$19.3M | -$19.9M | -$3.7M | -$5.8M | |
| Diluted EPS | -$0.74 | -$0.84 | -$0.76 | -$0.16 | -$0.22 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $70.4M | $58M | $46M | $47.6M | $24.2M | |
| Total Assets | $74.3M | $61.8M | $50.2M | $53.6M | $30.1M | |
| Current Liabilities | $3.1M | $4M | $6.1M | $15.2M | $6.9M | |
| Total Liabilities | $30.3M | $16M | $17.7M | $19.1M | $10.1M | |
| Total Equity | $44M | $45.7M | $32.6M | $34.6M | $20M | |
| Total Debt | $24.5M | $9.9M | $9.9M | $10M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$17.6M | -$11.9M | -$11.3M | -$3.8M | -$6.2M | |
| Cash From Investing | -$10.7M | $9.1M | -$458K | -- | -$183K | |
| Cash From Financing | $401K | $16.4M | -$11.2M | $16.1M | -$1.4M | |
| Free Cash Flow | -$18.7M | -$12.8M | -$11.7M | -$3.8M | -$6.4M | |
CLPT
Sector
Market Cap
$320.2M
$34.4M
Price % of 52-Week High
58.95%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
0.61%
-1.01%
1-Year Price Total Return
49.28%
-37.36%
Beta (5-Year)
0.917
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$11.69
200-day SMA
Sell
Level
$13.48
Bollinger Bands (100)
Sell
Level
11.41 - 14.27
Chaikin Money Flow
Buy
Level
472.1K
20-day SMA
Sell
Level
$11.60
Relative Strength Index (RSI14)
Sell
Level
44.15
ADX Line
Sell
Level
18.85
Williams %R
Neutral
Level
-67.0886
50-day SMA
Sell
Level
$12.33
MACD (12, 26)
Buy
Level
3.14
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Sell
Level
-378.1K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.4739)
Sell
CA Score
(Annual)
Level (-2.0229)
Buy
Beneish M-Score
(Annual)
Level (-3.1734)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.7125)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
Stock Forecast FAQ
In the current month, CLPT has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CLPT average analyst price target in the past 3 months is $29.00.
-
Where Will ClearPoint Neuro Stock Be In 1 Year?
According to analysts, the consensus estimate is that ClearPoint Neuro share price will rise to $29.00 per share over the next 12 months.
-
What Do Analysts Say About ClearPoint Neuro?
Analysts are divided on their view about ClearPoint Neuro share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ClearPoint Neuro is a Sell and believe this share price will drop from its current level to $28.00.
-
What Is ClearPoint Neuro's Price Target?
The price target for ClearPoint Neuro over the next 1-year time period is forecast to be $29.00 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CLPT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ClearPoint Neuro is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CLPT?
You can purchase shares of ClearPoint Neuro via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ClearPoint Neuro shares.
-
What Is The ClearPoint Neuro Share Price Today?
ClearPoint Neuro was last trading at $11.38 per share. This represents the most recent stock quote for ClearPoint Neuro. Yesterday, ClearPoint Neuro closed at $11.33 per share.
-
How To Buy ClearPoint Neuro Stock Online?
In order to purchase ClearPoint Neuro stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
